Empreendimentos Pague Menos stock (BRPGMNACNOR3): Q1 2026 shows double?digit growth but EPS miss weighs on sentiment

Empreendimentos Pague Menos delivered double?digit revenue and EBITDA growth in the first quarter of 2026, posting a 14.4% year?on?year increase in revenue and a record net income that more than quadrupled versus the prior?year quarter, according to a summary of the company’s Q1 2026 results published on TradingView on May 7, 2026.TradingView summary as of 05/07/2026

Despite the strong top?line and margin performance, the stock price of Pague Menos declined by about 0.37% following the earnings announcement, closing at BRL 5.39 on May 5, 2026, as investors reacted to an earnings?per?share miss and elevated expectations around profitability, according to an earnings?call transcript summary on Investing.com.Investing.com as of 05/05/2026

As of May 7, 2026, Empreendimentos Pague Menos S.A. was trading at BRL 5.01 on the Brazilian exchange, with a previous close of BRL 5.01 and intraday fluctuations within a narrow band, according to Investing.com’s quote page for PGMN3.Investing.com as of 05/07/2026

By the editorial team – specialized in equity coverage.

Empreendimentos Pague Menos: core business model

Empreendimentos Pague Menos S.A. operates as a pharmacy retail chain in Brazil, focusing on value?oriented health and personal?care products for a broad consumer base.Investing.com as of 05/07/2026

The company’s business model centers on a network of physical stores combined with an expanding digital channel, allowing customers to purchase prescription and over?the?counter medicines, cosmetics, hygiene items, and other health?related goods at competitive prices.Investing.com as of 05/07/2026

By emphasizing private?label brands and promotional campaigns, Pague Menos aims to maintain healthy gross margins while driving volume growth across its store footprint and online platform.Investing.com as of 05/07/2026

Main revenue and product drivers for Empreendimentos Pague Menos

In the first quarter of 2026, Empreendimentos Pague Menos reported 14.4% year?on?year revenue growth, reflecting both store?level expansion and higher same?store sales, according to a Quartr?sourced report summarized on TradingView.TradingView summary as of 05/07/2026

Net income for the quarter more than quadrupled compared with Q1 2025, supported by margin expansion and operating?leverage benefits from the higher sales base, the same report indicates.TradingView summary as of 05/07/2026

Digital sales rose to 22.2% of total revenue in Q1 2026, highlighting the growing importance of e?commerce and omnichannel strategies for the company’s growth profile, according to the Quartr?based summary.TradingView summary as of 05/07/2026

Why Empreendimentos Pague Menos matters for US investors

For US investors, Empreendimentos Pague Menos offers exposure to Brazil’s pharmacy and health?retail sector, which is influenced by demographics, healthcare access, and consumer spending trends in Latin America.Investing.com as of 05/07/2026

While the stock trades on the Brazilian exchange in BRL, it can be accessed via international brokers and ADR?style structures, allowing US?based portfolios to diversify into emerging?market consumer?health names with relatively low correlation to US?listed peers.Investing.com as of 05/07/2026

Recent double?digit revenue growth and a rising digital?sales share may appeal to investors seeking growth?oriented emerging?market equities, though currency and regulatory risks in Brazil remain important considerations.TradingView summary as of 05/07/2026

Conclusion

Empreendimentos Pague Menos posted strong double?digit revenue growth and a record net income in Q1 2026, with digital sales now accounting for more than one?fifth of total revenue, signaling progress in its omnichannel strategy.TradingView summary as of 05/07/2026

At the same time, the stock’s modest decline after the earnings release underscores that investors are scrutinizing earnings quality and margin sustainability, particularly in a high?inflation, high?interest?rate environment in Brazil.Investing.com as of 05/05/2026

For US investors, the name offers a leveraged play on Brazilian consumer?health demand and digital adoption, but also carries currency, regulatory, and macroeconomic risks that should be weighed carefully within a diversified portfolio.Investing.com as of 05/07/2026

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.